Refine by
Immune Antibody Articles & Analysis
16 news found
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV ...
Initial anti-glycan mAbs from the GlyMab™ platform have now been successfully humanised Fourth research agreement on Glymab™ platform signed with major European Pharma Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its anti-glycan monoclonal antibody (mAb) platform, now branded ...
ByScancell
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces an update regarding the South African Health Products Regulatory Authority’s (SAHPRA) approval of a protocol amendment to the Phase 1 COVIDITY clinical trial being conducted at the University of Cape Town (UCT) Lung Institute in South Africa. The ...
ByScancell
Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board The findings underscore the importance of new therapeutic approaches such as zapnometinib, which can maintain potent efficacy against all coronavirus strains, including Omicron Atriva Therapeutics ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities. Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM platform, which has demonstrated unprecedented control over T cell induction. World-class scientific team out of the NIH’s Vaccine Research Center with deep R&D capabilities. U.S. ...
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source. This treatments aims to be ...
Why HIV Testing is Important HIV Testing is critical to reducing its spread. The CDC recommends that all people ages 13-64 get tested at least once, and individuals deemed high risk should be tested more frequently. A positive test allows individuals to then seek treatment (there are several forms of effective treatment currently available) and prevent transmission to others. How HIV Testing ...
ByFluxergy
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and ...
OXFORD, UK – 7 April 2021: PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® ...
Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. This funding will allow the immunotherapy currently in pre-clinical studies to progress to Phase II clinical trials. In ...
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive ...
For COVID-19 testing, there are two predominant tests on the market: viral tests and serum antibody tests. Let’s take a look at the main differences between these two types of tests, like what they look for, when each is the most effective, and the logistics of providing each type. 1. Viral Tests Viral, or PCR, tests determine if an individual currently has COVID-19 by testing for the ...
ByMiraDx
Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company, today announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery and development of therapeutic antibodies in oncology. The ...
CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from: Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Université de Sherbrooke’s Professors ...
Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in the new EspaceLabz center, located in the Sherbrooke’s Scientific Park. In addition to providing additional space, the new facility will grant access to state-of-the-art equipment to follow the increasing demand for Immune Biosolutions’ ...